Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03674593 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 17, 2018
Last Update Posted : September 16, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Degenerative Mitral Valve Disease | Procedure: Mitral valve chordae prosthesis Procedure: Mitral valve chordae translocation | Not Applicable |
Summary: This study compares the efficacy and the safety of two surgical procedures for the treatment of mitral valve prolapse due to degeneration of the mitral valve: chordae replacement and the translocation of secondary mitral valve chordae.
In our study, researchers used the loop method proposed by von Oppel and Mohr in 2000. The main principle of the method of prosthetic chordae is the preservation of the native anatomy of the mitral valve. This principle is achieved by the implantation of artificial chordae made of ePTFE Gore-Tex threads.
The chordae replacement method essentially involves five stages:
- Measuring the required length of the chordae.
- Forming the loops.
- Fixation of the group of loops to the papillary muscles.
- Fixation of the chordal loops to the free edge of the valve.
- Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse.
Chordae translocation is the alternative method, which does not require measurement and selection of chordae lengths. Chordae replacement is technically easier (less aortic clamping time) with comparable results.
The technique of translocation of secondary chordae essentially consists of three stages:
- Selection of the secondary chordae.
- Fixation of secondary chordae to the free edge of the valve.
- Annuloplasty support ring and hydraulic test to confirm the absence of prolapse.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 64 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Single-center, prospective, semi-open, randomized study |
| Masking: | Single (Participant) |
| Masking Description: | Single blind masking (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Clinical and Fundamental Aspects of Prosthetics and Translocation of Mitral Valve Chordae |
| Actual Study Start Date : | July 9, 2018 |
| Estimated Primary Completion Date : | December 31, 2021 |
| Estimated Study Completion Date : | September 1, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Mitral valve chordae prosthesis
Patients of this group receive mitral valve chordae replacement performed in five stages:
|
Procedure: Mitral valve chordae prosthesis
The method consists of five stages:
Other Name: Chordae prosthesis |
|
Active Comparator: Mitral valve chordae translocation
The technique of translocation of secondary chordae: The method consists essentially of three stages:
|
Procedure: Mitral valve chordae translocation
The method consists essentially of three stages:
Other Name: Chordae translocation |
- Mitral regurgitation degree measure [ Time Frame: Two weeks ]Mitral regurgitation degree (from 1 to 4) assessed by echocardiography two weeks after surgery
- Surgical efficacy measure [ Time Frame: One year ]Mitral regurgitation degree (from 1 to 4) assessed by echocardiography one year after surgery
- ERO measure [ Time Frame: Two weeks ]Effective regurgitant orifice (ERO) (in square millimeters) assessed by echocardiography two weeks after surgery
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Isolated type II mitral valve insufficiency by A. Carpentier
- Mitral regurgitation degree >2
- Age >18 years
- Signed informed consent to participate in the study
Exclusion Criteria:
- Any other cardiac surgeries
- Age <18 years
- Multiple organ failure
- ReDo procedure
- Persistent atrial fibrillation
- Acute infective endocarditis
- Refusal to sign informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03674593
| Russian Federation | |
| Cardiology Research Institute, Tomsk NRMC | |
| Tomsk, Russian Federation, 634012 | |
| Principal Investigator: | Elena N. Pavlyukova, MD, PhD | Tomsk NRMC |
| Responsible Party: | Tomsk National Research Medical Center of the Russian Academy of Sciences |
| ClinicalTrials.gov Identifier: | NCT03674593 |
| Other Study ID Numbers: |
Mitral Valve Chordae |
| First Posted: | September 17, 2018 Key Record Dates |
| Last Update Posted: | September 16, 2021 |
| Last Verified: | September 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Mitral Valve Chordae Degenerative Mitral Valve Disease Mitral Valve Chordae Replacement Mitral Valve Chordae Translocation Mitral Valve Chordae Prosthetics |
|
Heart Valve Diseases Heart Diseases Cardiovascular Diseases |

